{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE306nnn/GSE306038/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306038"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Intratumoral plasma cells are required for immune checkpoint blockade therapy in de novo MPNSTs","description":"In most human cancers, intratumoral plasma cells connote improved patient survival and heightened anti-tumor response to immune checkpoint blockade (ICB) therapies, such as those targeting programmed death-ligand 1 (PD-L1) or programmed death 1 (PD1). Using an immunocompetent mouse model of de novo malignant peripheral nerve sheath tumors (MPNSTs), we found that plasma cells are required for successful anti-PD-L1 therapy and extended survival. In order to uncover the role of plasma cells in this response, we performed scRNA-seq of de novo MPNSTs within wild-type controls versus plasma cell-deficient AID-/-; µS-/- mice following CDK4/6-MEK inhibition. These results support our hypothesis that response to anti-PD-L1 is influenced by plasma cell infiltration into MPNSTs following CDK4/6-MEK inhibition.","dates":{"publication":"2026/08/19"},"accession":"GSE306038","cross_references":{"GSM":["GSM9191981","GSM9191980","GSM9191976","GSM9191979","GSM9191978","GSM9191977"],"GPL":["24247"],"GSE":["306038"],"taxon":["Mus musculus"],"PMID":["[42541926]"]}}